Perceptive Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Perceptive Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,620	Closed	-$1.06M	–	165
2017 Q1	$1.06M	Buy	+8,620	New	+$1.13M	0.06%	94
2016 Q1	–	Sell	-42,119	Closed	-$8.54M	–	190
2015 Q4	$8.54M	Sell	42,119 -10,000	-19%	-$1.79M	0.63%	38
2015 Q3	$7.57M	Sell	52,119 -3,144	-6%	-$577K	0.6%	42
2015 Q2	$11.8M	Sell	55,263 -49,377	-47%	-$12.1M	0.71%	36
2015 Q1	$24.2M	Hold	104,640	–	–	1.88%	13
2014 Q4	$24.1M	Buy	+104,640	New	+$22.4M	2.02%	14

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Perceptive Advisors's BLCM Position: Q2 2017 in Review

Perceptive Advisors sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2017, closing a stake of 8,620 shares — an estimated $1.06M sold.

Perceptive Advisors first reported a position in BLCM in Q4 2014 and held it in 6 quarters. The position peaked at $24.2M in Q1 2015. 84 funds tracked by Wall St. Rank hold BLCM as of Q2 2017.

Perceptive Advisors reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 8,620 Bellicum Pharmaceuticals, Inc. shares in Q2 2017, an estimated $1.06M.
Perceptive Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 6 quarters.
Perceptive Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $24.2M in Q1 2015.
84 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.